NDAENTERALSUSPENSION
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
DUOPA (carbidopa and levodopa) by AbbVie is dopa decarboxylase inhibitors [moa]. First approved in 2015.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOPA is a carbidopa/levodopa enteral suspension approved by FDA in 2015 for Parkinson's disease management. It delivers dopaminergic therapy directly to the small intestine via continuous infusion pump, bypassing gastric variability. The carbidopa component inhibits peripheral DOPA decarboxylase, allowing levodopa to reach the brain more effectively.
$0.003BPart D
PeakProduct is at peak lifecycle stage with modest Part D spending ($3M in 2023) and limited claims, suggesting stable but niche commercial footprint requiring specialized field and medical expertise.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
Started Jan 2016
213 enrolled
Advanced Parkinson's Disease
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Career Relevance
DUOPA careers are concentrated in specialty neurology sales, infusion device management, and patient support services within AbbVie's Commercial and Medical Affairs functions. Working on DUOPA offers deep clinical expertise in advanced Parkinson's care but operates in a niche market with limited headcount relative to larger franchises.
Worked on DUOPA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.